Table 3.

Follow-up data after pregnancy completion in 87 CML patients.

Follow-up data	All patients	Pregnancy outcome
	n = 87	Childbirth	Abortion/miscarriage
		n = 66	n = 21
Living status
Alive, n (%)	84 (97)	64 (97)	20 (95)
Dead, n (%)	3 (3)	2 (3)	1 (5)
First line TKI
Imatinib, n(%)	71 (82)	51 (77)	20 (95)
Dasatinib, n (%)	9 (10)	9 (14)	–
Nilotinib, n (%)	7 (8)	6 (9)	1 (5)
TKI switch, main reason
Resistance/suboptimal, n (%)	18 (21)	14 (21)	4 (19)
Intolerance/other, n (%)	6 (7)	4 (6)	2 (10)
No switch, n (%)	63 (72)	48(73)	15 (71)
Best overall response, n (%)
MMR	28 (32)	22 (33)	6 (29)
DMR	38 (44)	31 (47)	7 (33)
No MMR	12 (14)	8 (12)	4 (19)
No data	9 (10)	5 (8)	4 (19)